Neurocrine Biosciences, Inc.
At Close: 4:00 PM
NBIX Stock Price Graph
NBIX Stock Price Today
Neurocrine Biosciences, Inc. (NBIX) stock rallied over 0.60% intraday to trade at $112.84 a share on NASDAQ. The stock opened with a loss of -5.11% at $107.25 and touched an intraday high of $108.28, falling -0.16% against the last close of $113.02. The Neurocrine Biosciences, Inc. in stock market went to a low of $106.01 during the session.
NBIX Stock Snapshot
Number of Shares
Cash Flow per Share
Free Float in %
NBIX Stock Price History Chart
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Frequently Asked Questions
What is the current Neurocrine Biosciences, Inc. (NBIX) stock price?
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) stock price is $112.84 in the last trading session. During the trading session, NBIX stock reached the peak price of $108.28 while $106.01 was the lowest point it dropped to. The percentage change in NBIX stock occurred in the recent session was 0.60% while the dollar amount for the price change in NBIX stock was $0.67.
NBIX's industry and sector of operation?
The NASDAQ listed NBIX is part of Drug Manufacturers—Specialty & Generic industry that operates in the broader Healthcare sector. Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders.
Who are the executives of NBIX?
Dr. Kevin C. Gorman Ph.D.
Chief Executive Officer & Director
Mr. Darin M. Lippoldt Esq.
Chief Legal Officer & Corporation Sec.
Dr. Dimitri E. Grigoriadis
Chief Research Officer
Mr. David Warren Boyer
Chief Corporation Affairs Officer
How NBIX did perform over past 52-week?
NBIX's closing price is 0.27% higher than its 52-week low of $89.04 where as its distance from 52-week high of $129.29 is -0.26%.
How many employees does NBIX have?
Number of NBIX employees currently stands at N/A. NBIX operates from 12780 El Camino Real, San Diego, CA 92130, US.
Link for NBIX official website?
Official Website of NBIX is: https://www.neurocrine.com
How do I contact NBIX?
How many shares of NBIX are traded daily?
NBIX stock volume for the day was 618541.00 shares. The average number of NBIX shares traded daily for last 3 months was 670.05 Thousands.
What is the market cap of NBIX currently?
The market value of NBIX currently stands at $11.09 Billion with its latest stock price at $112.84 and N/A of its shares outstanding.